Codexis Inc CDXS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CDXS is a good fit for your portfolio.
News
-
Codexis to Report First Quarter 2024 Financial Results on May 2
-
Codexis Appoints Carole Cobb, MBA, to Strategic Advisory Board
-
Thinking about buying stock in Societal CDMO, LAVA Therapeutics, Eastman Kodak, Brightspring Health Services, or Codexis?
-
Codexis Reports Fourth Quarter and Fiscal Year 2023 Financial Results
-
Codexis Shares Up 31% on Roche Licensing Agreement
-
Codexis Enters Exclusive Licensing Agreement for Newly Engineered Double-Stranded DNA Ligase with Roche
-
Codexis to Participate in TD Cowen 44th Annual Health Care Conference
-
Codexis Announces Appointment of Masad Damha, PhD, and Jim Lalonde, PhD, to Strategic Advisory Board
Trading Information
- Previous Close Price
- $2.65
- Day Range
- $2.62–2.74
- 52-Week Range
- $1.45–4.91
- Bid/Ask
- $2.65 / $2.86
- Market Cap
- $187.01 Mil
- Volume/Avg
- 513,816 / 579,994
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.58
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Codexis Inc is involved in the business of providing enzyme optimization services, commercialization of proteins, and developing biocatalyst products, leveraging its proprietary CodeEvolver directed evolution technology platform. The firm's products and services include Biocatalysts and Enzymes. The company generates majority of its revenue through product sales and also licenses its technology platform CodeEvolver to pharmaceutical companies enabling them to use this technology, in-house, to engineer enzymes for their own businesses. Geographically, it derives revenue from the United States, Ireland, Switzerland, China and other markets.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 174
- Website
- https://www.codexis.com
Comparables
Valuation
|
Metric
|
CDXS
|
VCYT
|
TIHE
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 25.60 | — |
Price/Book Value | 2.15 | 1.35 | — |
Price/Sales | 2.58 | 3.89 | — |
Price/Cash Flow | — | 28.99 | — |
Price/Earnings
CDXS
VCYT
TIHE
Financial Strength
|
Metric
|
CDXS
|
VCYT
|
TIHE
|
|---|---|---|---|
Quick Ratio | 2.37 | 4.19 | — |
Current Ratio | 2.61 | 4.66 | — |
Interest Coverage | — | −5,596.07 | — |
Quick Ratio
CDXS
VCYT
TIHE
Profitability
|
Metric
|
CDXS
|
VCYT
|
TIHE
|
|---|---|---|---|
Return on Assets (Normalized) | −25.05% | 7.85% | — |
Return on Equity (Normalized) | −42.23% | 8.41% | — |
Return on Invested Capital (Normalized) | −35.12% | 7.64% | — |
Return on Assets
CDXS
VCYT
TIHE
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Hbyrdvpsb | Dsbj | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Gghmvcqpp | Gqgpw | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Sqwbxqxxd | Ljwrvwt | $97.8 Bil | |
MRNA
| Moderna Inc | Nnrmjjfl | Xlbdy | $41.3 Bil | |
ARGX
| argenx SE ADR | Zkxcfln | Kztg | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Ndnhrlkc | Jvjz | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Hhrwmgr | Ypxmql | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Rkrrlld | Vcsglb | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Sgggrtmjl | Vnxvhy | $12.5 Bil | |
INCY
| Incyte Corp | Tfrdsghmy | Rrvwlz | $11.6 Bil |